Table 1 Comparison of the baseline characteristics between surviving patients and those with operative mortality
From: Applying machine learning methods to predict operative mortality after tricuspid valve surgery
No mortality (n= 1049) | Mortality (n= 112) | P value | |
|---|---|---|---|
Age≥ 70 years | 150 (14.30%) | 34 (30.36%) | <0.001 |
Females | 649 (61.87%) | 62 (55.36%) | 0.179 |
BMI≥ 30 kg/m2 | 430 (40.99%) | 32 (28.57%) | 0.011 |
Hypertension | 400 (38.13%) | 68 (60.71%) | <0.001 |
Diabetes mellitus | 398 (37.94%) | 60 (53.57%) | 0.001 |
EuroSCORE II | 4.11 (2.29- 6.995) | 8.52 (4.745–20.035) | <0.001 |
Endocarditis | 17 (1.62%) | 7 (6.25%) | 0.001 |
COPD | 32 (3.05%) | 12 (10.71%) | <0.001 |
Heart failure within 1 year | 110 (10.49%) | 27 (24.11%) | <0.001 |
Previous stroke | 90 (8.59%) | 12 (10.71%) | 0.450 |
Atrial fibrillation | 393 (37.46%) | 43 (38.39%) | 0.847 |
Chronic kidney disease stage 4 | 131 (12.49%) | 37 (33.04%) | <0.001 |
Abnormal bilirubin≥ 21 µmmol/L | 118 (11.25%) | 13 (11.61%) | 0.909 |
NYHA III-IV | 834 (79.50%) | 95 (84.82%) | 0.181 |
Ejection fraction ≤ 40% | 203 (19.35%) | 25 (22.32%) | 0.452 |
PASP ≥ 50 mmHg | 648 (61.77%) | 81 (72.32%) | 0.028 |
Moderate/severe RV dysfunction | 76 (7.24%) | 15 (13.39%) | 0.021 |
Moderate/severe RV dilatation | 177 (16.87%) | 29 (25.89%) | 0.018 |
Emergency surgery | 30 (2.86%) | 12 (10.71%) | <0.001 |
Reoperative surgery | 269 (25.64%) | 47 (41.96%) | <0.001 |
Tricuspid valve replacement | 127 (12.11%) | 32 (28.57%) | <0.001 |
Isolated tricuspid surgery | 51 (4.86%) | 12 (10.71%) | 0.009 |
Beating tricuspid surgery | 145 (13.82%) | 20 (18.02%) | 0.229 |